CN119930509A - 靶向癌症干细胞的癌症治疗 - Google Patents

靶向癌症干细胞的癌症治疗 Download PDF

Info

Publication number
CN119930509A
CN119930509A CN202510009927.XA CN202510009927A CN119930509A CN 119930509 A CN119930509 A CN 119930509A CN 202510009927 A CN202510009927 A CN 202510009927A CN 119930509 A CN119930509 A CN 119930509A
Authority
CN
China
Prior art keywords
certain embodiments
alkyl
substituted
unsubstituted
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510009927.XA
Other languages
English (en)
Chinese (zh)
Inventor
Y·布鲁思-阿尔科尔
G·T·克里明斯
D·A·德耶稣迪亚兹
C·M·罗布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Treatment Solutions Inc
Original Assignee
Treatment Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treatment Solutions Inc filed Critical Treatment Solutions Inc
Publication of CN119930509A publication Critical patent/CN119930509A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
CN202510009927.XA 2019-11-06 2020-11-06 靶向癌症干细胞的癌症治疗 Pending CN119930509A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962931531P 2019-11-06 2019-11-06
US62/931,531 2019-11-06
PCT/US2020/059329 WO2021092322A1 (en) 2019-11-06 2020-11-06 Cancer treatments targeting cancer stem cells
CN202080091217.1A CN114929672B (zh) 2019-11-06 2020-11-06 靶向癌症干细胞的癌症治疗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080091217.1A Division CN114929672B (zh) 2019-11-06 2020-11-06 靶向癌症干细胞的癌症治疗

Publications (1)

Publication Number Publication Date
CN119930509A true CN119930509A (zh) 2025-05-06

Family

ID=73643356

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510009927.XA Pending CN119930509A (zh) 2019-11-06 2020-11-06 靶向癌症干细胞的癌症治疗
CN202080091217.1A Active CN114929672B (zh) 2019-11-06 2020-11-06 靶向癌症干细胞的癌症治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080091217.1A Active CN114929672B (zh) 2019-11-06 2020-11-06 靶向癌症干细胞的癌症治疗

Country Status (12)

Country Link
EP (1) EP4055008A1 (https=)
JP (2) JP7690470B2 (https=)
KR (1) KR20220110744A (https=)
CN (2) CN119930509A (https=)
AU (1) AU2020378067A1 (https=)
BR (1) BR112022008753A2 (https=)
CA (1) CA3157315A1 (https=)
CO (1) CO2022007910A2 (https=)
IL (1) IL292718A (https=)
MX (1) MX2022005445A (https=)
PH (1) PH12022551081A1 (https=)
WO (1) WO2021092322A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102831570B1 (ko) 2018-05-04 2025-07-10 레미디 플랜, 인크. 암 줄기 세포를 표적화하는 암 치료
JP2024518089A (ja) * 2021-05-13 2024-04-24 リメディー プラン，インコーポレーテッド Ｎａｍｐｔ阻害剤とその使用
WO2024049225A1 (ko) 2022-09-01 2024-03-07 주식회사 엘지에너지솔루션 이차 전지 및 이를 포함하는 디바이스
CN116139141A (zh) * 2022-12-14 2023-05-23 复旦大学 Agk2促进肝癌的免疫治疗的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
WO2008016643A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
FR2921657A1 (fr) * 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
CA2877474A1 (en) * 2011-06-20 2012-12-27 Myrexis, Inc. Compounds and therapeutic uses thereof
HK1211832A1 (zh) 2012-05-07 2016-10-14 The General Hospital Corporation 用於癌症療法的抗高血壓藥物的新穎配方及用法
ES2774330T3 (es) 2013-04-09 2020-07-20 Massachusetts Inst Technology Polímero de suministro de fármaco y usos del mismo
TW201625641A (zh) * 2014-05-22 2016-07-16 健臻公司 Ｎａｍｐｔ抑制劑及方法
US11078195B2 (en) * 2016-03-17 2021-08-03 Checkmate Therapeutics Inc. Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same
KR102831570B1 (ko) * 2018-05-04 2025-07-10 레미디 플랜, 인크. 암 줄기 세포를 표적화하는 암 치료

Also Published As

Publication number Publication date
JP2025143254A (ja) 2025-10-01
CO2022007910A2 (es) 2022-08-19
JP7690470B2 (ja) 2025-06-10
PH12022551081A1 (en) 2024-06-19
MX2022005445A (es) 2022-08-10
EP4055008A1 (en) 2022-09-14
CN114929672B (zh) 2025-01-21
IL292718A (en) 2022-07-01
AU2020378067A1 (en) 2022-05-26
JP2022553865A (ja) 2022-12-26
WO2021092322A1 (en) 2021-05-14
CN114929672A (zh) 2022-08-19
BR112022008753A2 (pt) 2022-07-19
CA3157315A1 (en) 2021-05-14
US20230023124A1 (en) 2023-01-26
KR20220110744A (ko) 2022-08-09

Similar Documents

Publication Publication Date Title
CN114929672B (zh) 靶向癌症干细胞的癌症治疗
CN112312899B (zh) 靶向癌症干细胞的癌症治疗
EP3092236B1 (en) Novel glutaminase inhibitors
AU2022200478B2 (en) Inhibitors of KEAP1-Nrf2 protein-protein interaction
WO2022266258A1 (en) Compounds and methods for the targeted degradation of irak-4
CA3042731A1 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
CN105073768A (zh) Ras抑制剂及其用途
US20240343727A1 (en) Pyridazinone or pyridinone compounds, preparation methods and uses thereof
CN113939518A (zh) 作为激酶抑制剂的稠合三环化合物
CN120659777A (zh) 募集Cereblon的Bcl-xL/Bcl-2双重降解剂
CA3217380A1 (en) Nampt inhibitors and uses thereof
WO2023107606A1 (en) Bcl-xl/bcl-2 dual degraders for treatment of cancers
CN113773315A (zh) 细胞周期蛋白依赖性激酶2（cdk2）高选择性氘代抑制剂
CN119490450A (zh) 一种含肟化合物及其用途
US12612368B2 (en) Cancer treatments targeting cancer stem cells
HK40120024A (zh) 靶向癌症干细胞的癌症治疗
CN110698460A (zh) 一种杂芳基类化合物、其制备方法、药物组合物和应用
CN118055926A (zh) Rock2抑制剂及其用途
KR20260027122A (ko) 치환된 스피로 화합물 유도체 및 이의 약제학적 용도
EP3471723A1 (en) Hedgehog acyltransferase inhibitors and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40120024

Country of ref document: HK